AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03892824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vine™ Embolic Protection System
Description: The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (Needle Unit) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled Loaded Needle Unit) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button.
Study NCT05019586 — intervention group
Intervention type: DRUG
Intervention: levofloxacin, amoxicillin, clarithromycin
Description: Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
Study NCT02615041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: 1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
Study NCT02615041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: 1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem.
Study NCT02615041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: 2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem.
Study NCT01218646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative
Description: 0.5 mL, Intramuscular
Study NCT01218646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Trivalent Inactivated Influenza Vaccine, No Preservative
Description: 0.5 mL, Intramuscular
Study NCT01218646 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
Description: 0.5 mL, Intramuscular
Study NCT03360500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE PROTOCOL + CRYOTHERAPY
Description: Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Cryotherapy: Crushed ice inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field.
Study NCT03360500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE PROTOCOL
Description: Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.
Study NCT03360500 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EXERCISE PROTOCOL + PLACEBO
Description: Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Placebo: Sand inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sandbags, they will be fixed with an elastic bandage (compression). All the knee surface will be covered with a moistened operative field.
Study NCT02375243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine continous infusion 0.5 mcg/kg/h
Study NCT06526442 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging
Description: all participants undergo novel MR sequences, including 3D-MRE，DCE-MRI，IVIM-DWI，T1/T2 mapping.
Study NCT04018937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab will be administered by either subcutaneous (SQ) injection or IV. A test dose of alemtuzumab, 3 mg, is administered on the first day. If the test dose is tolerated, administration of three treatment doses will begin within 24 hours. The three treatment doses will be administered on consecutive days. On the first day, 10 mg/m2 will be given, 15 mg/m\^2 the second and 20 mg/m\^2 the third. Alemtuzumab will be started between Days -22 and -20, but all doses (test dose and three treatment doses) should be completed by Day -18.
Study NCT04018937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered at 30 mg/m\^2 IV daily for five days (Days -7 to -3).
Study NCT04018937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be administered at 140 mg/m\^2 IV on Day -3 following fludarabine administration.
Study NCT02509819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heel Cushion Material Bulk (foam)
Description: The heel wedge is made of a rubber style urethane foam. Heel wedges of specified heights and durometers will be inserted into the standard shoes, one at a time, during the test session only. The heel wedges used during the test session are made of the same foam as the heel wedges that are used clinically.
Study NCT01628432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conservative hysterectomy I
Description: conservative hysterectomy for benign disease
Study NCT01628432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative hysterectomy II
Description: bilateral salpingectomy during hysterectomy without conservation of the ovaries
Study NCT01472861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AECC (Autologous endometrial coculture)
Description: endometrial biopsy with autologous endometrial coculture
Study NCT01472861 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no endometrial biopsy or Autologous endometrial coculture (AECC) performed
Description: routine procedures with out biopsy
Study NCT02675036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Study NCT00762710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin medication
Description: Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg
Study NCT00762710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication
Description: Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg
Study NCT01244438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-1039
Description: FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
Study NCT01729390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density and portion size feeding study
Description: In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).
Study NCT03332355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-1 Compound
Description: PAC-1 in combination with temozolomide (Component 2): after the MTD is established for single agent PAC-1 in Component 1, a modified-Fibonacci dose-escalation 3+3 design starts in Component 2, at a PAC-1 dose one level lower than the MTD of PAC-1 established in the single agent PAC-1 component (i.e., Component 1). PAC-1 will be taken in the morning on days 1-21 in each 28 day cycle. Temozolomide 150 mg/m2 dose is given for the 5 days starting at day 8 of cycle 1 in cohorts of 3-6 patients. The combination cohort that reaches MTD will expanded to at least 9 patients, similar to the PAC-1 alone cohort at MTD.
Study NCT01090778 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Norditropin SimpleXx (growth hormone)
Description: 3mg/subject/day over two consecutive days
Study NCT00576589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-326,597
Description: CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.
Study NCT00576589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
Study NCT02075567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental
Study NCT02655614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0134
Description: GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.
Study NCT02655614 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GDC-0134
Description: GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.
Study NCT02655614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to GDC-0134
Study NCT02655614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 20 mg twice daily orally
Study NCT02655614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole
Description: Rabeprazole 20 mg twice daily orally
Study NCT02655614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2mg of liquid formulation of midazolam orally
Study NCT02655614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: 2mg of liquid formulation of midazolam orally
Study NCT02655614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 100 mg tablet or solution of caffeine orally
Study NCT02655614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: 100 mg tablet or solution of caffeine orally
Study NCT02764892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V81444
Description: Single oral dose of V81444
Study NCT03290976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:~Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5
Study NCT03290976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modality (Acupuncture plus)
Description: A number of additional CIM treatment modalities will be added to the acupuncture treatment in this arm of the study, in accordance with the practitioners available at each of the participating study centers. These will include one of more of the following:~* Manual-movement therapies - e.g. acupressure/reflexology, self- and caregiver-practiced acupressure~* Mind-body therapies - e.g. relaxation/imagery method, Anthroposophic music therapy The multimodal CIM treatment regimen will be re-evaluated at each session, and adapted according to the concerns and expectations of the patients, as well as the recommendation of the treating CIM practitioner.
Study NCT03328468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise
Description: Breathing exercise for stroke patients
Study NCT03669640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889450
Description: Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
Study NCT03669640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
Study NCT00049010 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: comparative genomic hybridization
Study NCT00049010 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Study NCT00049010 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Study NCT00049010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT03035981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice, low amylose
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response
Study NCT03035981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice, high amylose
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response
Study NCT03035981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice, slow
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response
Study NCT03035981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice, resistant
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response
Study NCT03035981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown rice, low amylose
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response
Study NCT03035981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown rice, high amylose
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response
Study NCT03035981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharide (FOS)
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response
Study NCT02830646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DFG mesure
Description: Measure the effect of gastric bypass on the report DFG / VEC.
Study NCT02487407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-109
Description: ODM-109 1 mg capsule for oral administration.
Study NCT02487407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ODM-109
Description: ODM-109 1 mg capsule for oral administration.
Study NCT02487407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ODM-109
Description: Placebo capsule for oral administration.
Study NCT01051310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve System
Description: Transcatheter Aortic Valve
Study NCT03939793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPaCT Community Health Worker
Description: Once a CHW receives notification of a struggling patient, the CHW will visit the patient at their home within 1-2 days to initiate the IMPaCT intervention.~1. Elements of the standard IMPaCT intervention: During the first home visit, the CHW will use an in-depth semi-structured interview guide to get to know patients holistically and assess for unmet socioeconomic needs. This allows patients to express goals in line with their own needs and preferences. These individualized goals will become the basis for tailored action plans. The CHW will then provide hands-on, tailored support for the remainder of the 24-week study period to help patients achieve their goals.~2. Additional elements to help patients cope with failure: In this study, we will test a refined version of IMPaCT that incorporates two behavioral techniques for coping with failure: positive affect induction and attribution retraining.
Study NCT03939793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital health monitoring with financial incentives
Description: Participants are encouraged to use their glucometer to check their blood glucose via bidirectional texting and lottery-based financial incentives, which both serve to reinforce self-monitoring behavior.
Study NCT03939793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital health monitoring with financial incentives
Description: Participants are encouraged to use their glucometer to check their blood glucose via bidirectional texting and lottery-based financial incentives, which both serve to reinforce self-monitoring behavior.
Study NCT04696302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus of attention
Description: Individuals were asked to laterally weight shift while seated with either internal focus or external focus instructions.
Study NCT01125397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEARN group
Description: Participants will complete a 12-week behavioral weight management intervention (the LEARN program) prior to bariatric surgery, which is the current standard clinical practice at Mayo Clinic Rochester. This involves weekly group meetings, weigh-ins, and goal setting.
Study NCT00571324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39)
Description: A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.
Study NCT00571324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exendin-(9-39)
Description: A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.
Study NCT00571324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.
Study NCT00571324 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.
Study NCT01358435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30% Regular Insulin Human Neutral and 70%Isophane Insulin
Description: Total Dose per subject is 0.4 IU/Kg given subcutaneously.
Study NCT01358435 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novolin 70/30
Description: Total Dose per subject is 0.4IU/Kg given Subcutaneously.
Study NCT01268553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Transition to inhaled treprostinil
Study NCT02487407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ODM-109
Description: Placebo capsule for oral administration.
Study NCT03939793 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT01296776 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: wellness control group.
Description: Light physical exercise and relaxation program once a week in blocks of 10 weeks with breaks of 10 weeks between the blocks. The low-intensity, low-volume program was designed to avoid impact on our endpoints.
Study NCT01296776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whole-body electromyostimulation
Description: 3 sessions of 18 min/14 (1,5 x week)days over 12 months. 10 low-intensity/low amplitude exercises with electromyostimulation equipment with 85 Hz with periods of 6 sec of current and 4 sec of rest.
Study NCT04344899 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Enhanced Recovery After Surgery protocol at five tertiary-care pediatric hospitals in pediatric patients undergoing abdominal or retroperitoneal surgical resections for cancer.
Study NCT03287141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Shuttle walk test
Description: A shuttle walk test was performed without any previous intervention.
Study NCT03287141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (Bi-pap)
Description: After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
Study NCT03287141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (CPAP)
Description: After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.